Affinity Asset Advisors LLC Decreases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Affinity Asset Advisors LLC lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 50.0% during the 4th quarter, HoldingsChannel reports. The firm owned 25,000 shares of the company’s stock after selling 25,000 shares during the period. Affinity Asset Advisors LLC’s holdings in Vaxcyte were worth $2,046,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Vaxcyte by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after buying an additional 521,204 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Vaxcyte by 3.0% in the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company’s stock valued at $234,884,000 after acquiring an additional 82,997 shares during the period. Geode Capital Management LLC boosted its position in Vaxcyte by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company’s stock worth $229,495,000 after purchasing an additional 102,106 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Vaxcyte by 8.1% during the 4th quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company’s stock valued at $145,659,000 after purchasing an additional 133,448 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Vaxcyte by 3.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,341,773 shares of the company’s stock valued at $109,838,000 after purchasing an additional 45,936 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Up 2.7 %

NASDAQ PCVX opened at $32.04 on Tuesday. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock’s 50 day moving average is $65.25 and its 200 day moving average is $84.98. The stock has a market cap of $4.13 billion, a PE ratio of -6.97 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. The trade was a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock valued at $3,170,738 in the last 90 days. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PCVX. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group decreased their price objective on Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.